Chemicon International Inc

Receive alerts:
by e-mail
E-mail Your information will be added to a database with the sole purpose of serving your subscription. This database is the exclusive property of vLex Networks S.L. and will never be shared with any other company. By sending your request you accept the Data Protection Policy of vLex Networks S.L. I have read and accept the Terms of Use
via RSS

88 documents for Chemicon International Inc

- Chemicon International, Inc. Enters into a License to Commercialize Research Products Utilizing Human Embryonic Stem Cell Technology from Wisconsin Alumni Research Foundation (WARF).
ATLANTA -- Serologicals Corporation (NASDAQ: SERO) announced today that Chemicon International, Inc., its wholly-owned subsidiary based in Temecula, C...
- Business Wire
- July 25, 2005
- Chemicon International, Inc. Licenses Its Patented Amplifluor Technology for Cancer Diagnostics to Oncomethylome Sciences S.A.
ATLANTA -- Serologicals Corporation (NASDAQ: SERO) announced today that Chemicon International, Inc., its wholly-owned subsidiary and OncoMethylome Sc...
- Business Wire
- March 30, 2005
- Chemicon International, Inc. Releases Innovative Infectious Disease Detection Product.
ATLANTA -- Serologicals Corporation (NASDAQ: SERO) announced today that Chemicon International, Inc., its wholly-owned subsidiary based in Temecula, C...
- Business Wire
- September 22, 2005

- Chemicon International, Inc., a Division of Serologicals Corporation, Acquires Mouse Embryonic Stem Cell Product Lines from Primogenix Incorporated.
ATLANTA -- Chemicon International, Inc., a division of Serologicals Corporation (NASDAQ/NM: SERO), and Primogenix Incorporated today announced that Ch...
- Business Wire
- November 03, 2004
- Chemicon International, Inc. Expands its Exclusive Agreement for Patented Compounds and Methods for Embryonic Stem - ES - Cell Research.
ATLANTA & MELBOURNE, Australia -- Serologicals Corporation (NASDAQ: SERO) announced today that Chemicon International, Inc., its wholly-owned subsidia...
- Business Wire
- April 05, 2005
- Chemicon International, Inc. Meets CE Mark Deadline for Its Light Diagnostic Products.
Business Editors/Health/Medical Writers TEMECULA, Calif.--(BUSINESS WIRE)--Dec. 8, 2003 Chemicon International, Inc., a division of Serologicals C...
- Business Wire
- December 08, 2003
- Chemicon International, Inc. Enters into License Agreement with RheoGene, Inc. to Commercialize Research Products Utilizing RheoSwitch(R) Inducible Gene Regulation Technology.
ATLANTA -- Serologicals Corporation (NASDAQ: SERO) announced today that Chemicon International, Inc., its wholly-owned subsidiary based in Temecula, C...
- Business Wire
- November 28, 2005
- Chemicon International, Inc. Expands Stem Cell Franchise Through Acquisition of Specialty Media.
ATLANTA -- Serologicals Corporation (NASDAQ: SERO) announced today that Chemicon International, Inc., its wholly-owned subsidiary, has acquired the as...
- Business Wire
- February 22, 2005
- Chemicon International, Inc. Licenses Quantum Dot Antibody Reagent Line from Quantum Dot Corporation.
ATLANTA & HAYWARD, Calif. -- Chemicon International, a subsidiary of Serologicals Corporation (NASDAQ: SERO), and Quantum Dot Corporation (QDC) today ...
- Business Wire
- March 04, 2005
- Serologicals Corporation's Research Division, Chemicon International, Inc. Enters into Exclusive License Agreement with Genome Biosciences, Inc.
Business Editors/Health/Medical Writers TEMECULA, Calif.--(BUSINESS WIRE)--Nov. 18, 2003 Chemicon International, Inc. ("Chemicon"), a division of ...
- Business Wire
- November 18, 2003